ClinicalTrials.Veeva

Menu

Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Chronic Obstructive Pulmonary Disease

Study type

Observational

Funder types

Industry

Identifiers

NCT00837629
NIS-RSI-SYM-2006/1

Details and patient eligibility

About

This non-interventional study is to analyse the therapeutic effectiveness in patients with severe COPD following a generally accepted 12-week treatment period with Symbicort Turbuhaler, which could anyhow be shortened or extended at physician's discretion.

Enrollment

743 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • non pregnant female
  • COPD with persistent symptoms in spite of regular bronchodilator therapy
  • Naive or fixed combination treated patients including patients already on Symbicort Turbuhaler

Exclusion criteria

  • Hypersensitivity to budesonide, formoterol or inhaled lactose

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems